Objectives (1) To identify the cost‐driving factors of health expenditure in inflammatory bowel disease (IBD), (2) to determine the effect of different cost‐sharing levels on outpatient visits and (3) to determine the effect of different cost‐sharing levels on medication adherence among patients with IBD. Method This was a retrospective, longitudinal study in which data were collected from 1999 to 2013 using the Medical Expenditure Panel Survey. The study sample included all patients who had IBD, were at least 18 years old, and had insurance. A comprehensive list of demographic factors was assessed to identify cost‐driving factors associated with high level of expenditure in IBD. Two logistic regression models were built to examine the association between outpatient cost sharing and number of outpatient visits, and between prescription cost sharing and medication adherence. Statistical significance was evaluated at P < 0.05. Key findings Significant cost‐driving factors included age, body mass index, education, income, quality of life, Charlson Comorbidity Index and region. The study found that low outpatient cost sharing was associated significantly with high level of outpatient visits. However, different levels of prescription cost sharing had no significant relationship with medication adherence. Conclusions The finding confirms the existence of financial barriers to care in IBD, which may lead to suboptimal outpatient and, thus, the rapid worsening of the diseases. The finding of cost‐driving factors allows the identification of high‐risk group for high expenditure, which can be used for future cost‐saving strategy.

Objectives: One of the most common complications of diabetes is painful diabetic peripheral neuropathy (PDPN), which has been increasing in prevalence. Published guidelines recommend a number of medications to treat PDPN providing clinicians with a variety of treatment options. There have been multiple cost effectiveness studies comparing pregabalin to other antidepressant medications such as duloxetine and despiramine. However, there has not been a study that compares the cost effectiveness of pregabalin and venlafaxine. This research aims to compare the quality adjusted life year, costs, and cost effectiveness of Pregabalin vs. Venlafaxine. MethOds: Published and unpublished clinical trial ad cross-sectional data were integrated into a decision analytic model to estimate the costs of treatment for painful diabetic neuropathy over 3-month (base case), 1-month and 6-month time frames used for sensitivity analysis. Efficacy was measured by using quality adjusted life years (QALYs), and costs were measured in $US, using a third party payer perspective. Results: Pregabalin is more effective and less expensive than Venlafaxine in the base case analysis and through a range of sensitivity analysis. The incremental cost-effectiveness ration (ICER) for pregabalin relative to venlafaxine was $US4552.60 per QALY. cOnclusiOns: Pregabalin is more cost effective than Venlafaxine for treating painful diabetic neuropathy, depending on the willingness to pay threshold. The estimated value of pregabalin and venlafaxine depends on the assumptions made in the statistical analyses. PND27 Cost-Utility ANAlysis of iNtrAmUsCUlAr iNterferoN BetA-1B VersUs sUBCUtANeoUs iNterferoN BetA-1B AND BetA-1A iN PAtieNts with relAPsiNg-remittiNg mUltiPle sClerosis iN ColomBiA

No abstract